<DOC>
	<DOCNO>NCT01105325</DOCNO>
	<brief_summary>To study compliance secondary prevention first month follow discharge cardiac intensive care unit ( CIC ) patient experience first episode acute coronary syndrome : quantitative compliance 3 month two principal treatment prescription ( statin - rosuvastatin , Crestor® platelet aggregation inhibitor - clopidogrel , Plavix® ) , use electronic measure system ( `` intelligent blister '' pack® ) ;</brief_summary>
	<brief_title>Evaluation Compliance With Management Acute Coronary Syndrome Discharge From Cardiac Intensive Care</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>Patient admit CIC unit first episode acute coronary syndrome , CIC cardiologist considers Crestor® rosuvastatin appropriate statin , combination platelet aggregation inhibitor ( Plavix®clopidogrel ) Patient give his/her oral consent participate study . Patient previously treat lipidlowering drug . Patient known history coronary heart disease . Patient whose treatment discharge comprise one two study treatment Patient participate participate previous 3 month biomedical research study cardiology .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>acute coronary syndrome</keyword>
	<keyword>treatment compliance</keyword>
	<keyword>cardiac intensive care unit</keyword>
	<keyword>secondary prevention</keyword>
	<keyword>cardiac intensive care unit ( CIC )</keyword>
	<keyword>compliance</keyword>
	<keyword>intensive care</keyword>
</DOC>